Does the media refer more to RGNX or NGEN?

In the previous week, REGENXBIO had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 4 mentions for REGENXBIO and 3 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of 0.62 beat REGENXBIO's score of 0.38 indicating that NervGen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, RLMD or NGEN?

NervGen Pharma is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A NervGen Pharma N/A N/A N/A -$0.09 N/A

Is RLMD or NGEN more profitable?

NervGen Pharma's return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -71.22% -64.46% NervGen Pharma N/A N/A N/A

Does the media prefer RLMD or NGEN?

In the previous week, Relmada Therapeutics had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 4 mentions for Relmada Therapeutics and 3 mentions for NervGen Pharma. Relmada Therapeutics' average media sentiment score of 1.74 beat NervGen Pharma's score of 0.62 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NGEN or STTK more profitable?

NervGen Pharma's return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A N/A N/A Shattuck Labs N/A -60.73% -55.75%

Does the media favor NGEN or STTK?

In the previous week, Shattuck Labs had 8 more articles in the media than NervGen Pharma. MarketBeat recorded 11 mentions for Shattuck Labs and 3 mentions for NervGen Pharma. Shattuck Labs' average media sentiment score of 0.69 beat NervGen Pharma's score of 0.62 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, EIKN or NGEN?

NervGen Pharma is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A N/A -$2.46 N/A NervGen Pharma N/A N/A N/A -$0.09 N/A

Is EIKN or NGEN more profitable?

Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A NervGen Pharma N/A N/A N/A

Does the media favor EIKN or NGEN?

In the previous week, Eikon Therapeutics and Eikon Therapeutics both had 3 articles in the media. Eikon Therapeutics' average media sentiment score of 0.62 beat NervGen Pharma's score of 0.62 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NervGen Pharma (NGEN) Competitors

$1.63 -0.05 (-2.69%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.68 +0.06 (+3.37%)

As of 07/24/2026 07:34 PM Eastern

Compare

NGEN vs. ALT, RGNX, RLMD, STTK, and EIKN

Should you buy NervGen Pharma stock or one of its competitors? MarketBeat compares NervGen Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NervGen Pharma include Altimmune (ALT), REGENXBIO (RGNX), Relmada Therapeutics (RLMD), Shattuck Labs (STTK), and Eikon Therapeutics (EIKN). These companies are all part of the "pharmaceutical products" industry.

How does NervGen Pharma compare to Altimmune?

NervGen Pharma (NASDAQ:NGEN) and Altimmune (NASDAQ:ALT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

78.1% of Altimmune shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, NervGen Pharma had 2 more articles in the media than Altimmune. MarketBeat recorded 3 mentions for NervGen Pharma and 1 mentions for Altimmune. Altimmune's average media sentiment score of 1.89 beat NervGen Pharma's score of 0.62 indicating that Altimmune is being referred to more favorably in the news media.

Company	Overall Sentiment
NervGen Pharma	Positive
Altimmune	Very Positive

NervGen Pharma has higher earnings, but lower revenue than Altimmune. NervGen Pharma is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A
Altimmune	$36K	14,963.69	-$88.09M	-$0.93	N/A

NervGen Pharma presently has a consensus target price of $14.00, suggesting a potential upside of 758.90%. Altimmune has a consensus target price of $15.71, suggesting a potential upside of 467.30%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NervGen Pharma is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

NervGen Pharma has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. NervGen Pharma's return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Altimmune	-214,860.98%	-42.57%	-35.57%

Summary

NervGen Pharma beats Altimmune on 9 of the 14 factors compared between the two stocks.

How does NervGen Pharma compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

88.1% of REGENXBIO shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NervGen Pharma has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. NervGen Pharma's return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
NervGen Pharma	N/A	N/A	N/A

NervGen Pharma has lower revenue, but higher earnings than REGENXBIO. NervGen Pharma is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.95	-$193.88M	-$5.60	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

In the previous week, REGENXBIO had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 4 mentions for REGENXBIO and 3 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of 0.62 beat REGENXBIO's score of 0.38 indicating that NervGen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

REGENXBIO currently has a consensus target price of $23.82, suggesting a potential upside of 144.79%. NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 758.90%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

NervGen Pharma beats REGENXBIO on 8 of the 14 factors compared between the two stocks.

How does NervGen Pharma compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

NervGen Pharma's return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
NervGen Pharma	N/A	N/A	N/A

45.2% of Relmada Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 5.8% of NervGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Relmada Therapeutics had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 4 mentions for Relmada Therapeutics and 3 mentions for NervGen Pharma. Relmada Therapeutics' average media sentiment score of 1.74 beat NervGen Pharma's score of 0.62 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NervGen Pharma is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

Relmada Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 131.66%. NervGen Pharma has a consensus target price of $14.00, indicating a potential upside of 758.90%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NervGen Pharma is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Relmada Therapeutics and NervGen Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does NervGen Pharma compare to Shattuck Labs?

NervGen Pharma (NASDAQ:NGEN) and Shattuck Labs (NASDAQ:STTK) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

NervGen Pharma presently has a consensus target price of $14.00, suggesting a potential upside of 758.90%. Shattuck Labs has a consensus target price of $12.63, suggesting a potential upside of 69.92%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NervGen Pharma is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

58.7% of Shattuck Labs shares are owned by institutional investors. 5.8% of NervGen Pharma shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NervGen Pharma's return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Shattuck Labs	N/A	-60.73%	-55.75%

NervGen Pharma has higher earnings, but lower revenue than Shattuck Labs. NervGen Pharma is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A
Shattuck Labs	$1M	569.74	-$48.81M	-$0.63	N/A

In the previous week, Shattuck Labs had 8 more articles in the media than NervGen Pharma. MarketBeat recorded 11 mentions for Shattuck Labs and 3 mentions for NervGen Pharma. Shattuck Labs' average media sentiment score of 0.69 beat NervGen Pharma's score of 0.62 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shattuck Labs	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Shattuck Labs beats NervGen Pharma on 7 of the 13 factors compared between the two stocks.

How does NervGen Pharma compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and NervGen Pharma (NASDAQ:NGEN) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
NervGen Pharma	N/A	N/A	N/A

In the previous week, Eikon Therapeutics and Eikon Therapeutics both had 3 articles in the media. Eikon Therapeutics' average media sentiment score of 0.62 beat NervGen Pharma's score of 0.62 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics presently has a consensus price target of $25.20, indicating a potential upside of 183.15%. NervGen Pharma has a consensus price target of $14.00, indicating a potential upside of 758.90%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

NervGen Pharma is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

Summary

NervGen Pharma beats Eikon Therapeutics on 4 of the 7 factors compared between the two stocks.

Get NervGen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGEN vs. The Competition

Export

Metric	NervGen Pharma	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$131.43M	$3.11B	$7.24B	$12.26B
Dividend Yield	N/A	15.21%	40.99%	9.79%
P/E Ratio	-18.11	13.16	23.62	23.64
Price / Sales	N/A	2,709.07	132.14	89.45
Price / Cash	N/A	25.90	165.01	59.64
Price / Book	N/A	9.39	12.77	6.07
Net Income	N/A	-$34.07M	$120.21M	$331.99M
7 Day Performance	-2.40%	0.44%	-0.98%	-0.63%
1 Month Performance	-14.66%	0.09%	-2.00%	-2.00%
1 Year Performance	N/A	9.86%	9.75%	13.62%

NervGen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGEN NervGen Pharma	2.3413 of 5 stars	$1.63 -2.7%	$14.00 +758.9%	N/A	$131.43M	N/A	N/A	N/A	Analyst Forecast
ALT Altimmune	2.389 of 5 stars	$2.83 -1.6%	$15.71 +456.3%	-32.6%	$551.32M	$40K	N/A	50	Positive News
RGNX REGENXBIO	3.8587 of 5 stars	$10.35 +4.6%	$23.82 +130.2%	+6.6%	$540.21M	$170.44M	N/A	370
RLMD Relmada Therapeutics	2.4161 of 5 stars	$5.14 -1.9%	$12.00 +133.5%	+678.7%	$539.14M	N/A	N/A	10	News Coverage Positive News
STTK Shattuck Labs	3.072 of 5 stars	$6.97 -7.4%	$13.00 +86.5%	+754.9%	$536.76M	$1M	N/A	100	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGEN) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NervGen Pharma (NGEN) Competitors

NGEN vs. ALT, RGNX, RLMD, STTK, and EIKN

How does NervGen Pharma compare to Altimmune?

Summary

How does NervGen Pharma compare to REGENXBIO?

Summary

How does NervGen Pharma compare to Relmada Therapeutics?

Summary

How does NervGen Pharma compare to Shattuck Labs?

Summary

How does NervGen Pharma compare to Eikon Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NervGen Pharma (NGEN) Competitors

NGEN vs. ALT, RGNX, RLMD, STTK, and EIKN

How does NervGen Pharma compare to Altimmune?

Do insiders & institutionals believe in NGEN or ALT?

Does the media prefer NGEN or ALT?

Which has better earnings & valuation, NGEN or ALT?

Do analysts prefer NGEN or ALT?

Is NGEN or ALT more profitable?

Summary

How does NervGen Pharma compare to REGENXBIO?

Do insiders and institutionals hold more shares of RGNX or NGEN?

Is RGNX or NGEN more profitable?

Which has stronger valuation & earnings, RGNX or NGEN?

Does the media refer more to RGNX or NGEN?

Do analysts prefer RGNX or NGEN?

Summary

How does NervGen Pharma compare to Relmada Therapeutics?

Is RLMD or NGEN more profitable?

Do insiders and institutionals believe in RLMD or NGEN?

Does the media prefer RLMD or NGEN?

Which has better valuation and earnings, RLMD or NGEN?

Do analysts prefer RLMD or NGEN?

Summary

How does NervGen Pharma compare to Shattuck Labs?

Do analysts prefer NGEN or STTK?

Do institutionals and insiders hold more shares of NGEN or STTK?

Is NGEN or STTK more profitable?

Which has higher valuation and earnings, NGEN or STTK?

Does the media favor NGEN or STTK?

Summary

How does NervGen Pharma compare to Eikon Therapeutics?

Is EIKN or NGEN more profitable?

Does the media favor EIKN or NGEN?

Do analysts rate EIKN or NGEN?

Which has better valuation & earnings, EIKN or NGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools